Cargando…

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

EBV infection causes mononucleosis and is associated with specific subsets of B cell lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly susceptible to EBV-induced lymphoproliferative disease (LPD), which can be fatal. Leflunomide (a drug used to treat rheumatoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilger, Andrea, Plowshay, Julie, Ma, Shidong, Nawand ar, Dhananjay, Barlow, Elizabeth A., Romero-Masters, James C., Bristol, Jillian A., Li, Zhe, Tsai, Ming-Han, Delecluse, Henri-Jacques, Kenney, Shannon C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546479/ https://www.ncbi.nlm.nih.gov/pubmed/28574826 http://dx.doi.org/10.18632/oncotarget.17863

Ejemplares similares

Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells
por: Van Sciver, Nicholas, et al.
Publicado: (2021)

B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection
por: Romero-Masters, James C., et al.
Publicado: (2020)

DNA Damage Signaling Is Induced in the Absence of Epstein—Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA
por: Wang'ondu, Ruth, et al.
Publicado: (2015)

A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection
por: Bristol, Jillian A., et al.
Publicado: (2018)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019)

An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model
por: Romero-Masters, James C., et al.
Publicado: (2018)

Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
por: Tatfi, Moussab, et al.
Publicado: (2019)

Painful Small Fiber Neuropathy Associated With Teriflunomide: A Case Series and Literature Review Related to Teriflunomide and Leflunomide
por: Elrefaey, Ahmed, et al.
Publicado: (2023)

Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells
por: Nawandar, Dhananjay M., et al.
Publicado: (2015)

Complexities associated with expression of Epstein–Barr virus (EBV) lytic origins of DNA replication
por: Xue, Shao-An, et al.
Publicado: (2007)

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
por: Li, Hongde, et al.
Publicado: (2018)

Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide
por: Terekhova, Irina, et al.
Publicado: (2020)

Epstein–Barr Virus (EBV) Rta-Mediated EBV and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivations in 293 Cells
por: Chen, Yen-Ju, et al.
Publicado: (2011)

Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man
Publicado: (1991)

Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells
por: Bristol, Jillian A., et al.
Publicado: (2022)

On the interactions of leflunomide and teriflunomide within receptor cavity — NMR studies and energy calculations
por: Kujawski, Jacek, et al.
Publicado: (2015)

Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is an Epstein-Barr virus (EBV) associated disease()()
por: Ordoñez-Parra, Juliana, et al.
Publicado: (2021)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?
por: Pace, Romina, et al.
Publicado: (2013)

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies
por: Choi, Chung King, et al.
Publicado: (2015)

641. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorder in EBV Seropositive Adult Lung Transplant Recipients
por: Heldman, Madeleine R, et al.
Publicado: (2023)

Simiao Qingwen Baidu decoction inhibits Epstein–Barr virus-induced B lymphoproliferative disease and lytic viral replication
por: Yang, Xianhui, et al.
Publicado: (2021)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Burkitt's lymphoma: differential killing of Epstein-Barr virus (EBV) (+) and EBV(-) Burkitt lymphoma cells in vitro and dose-dependent lytic induction by bortezomib in vivo
por: Dufresne, AL, et al.
Publicado: (2009)

Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription
por: Ali, Ahmed, et al.
Publicado: (2022)

Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib
por: Hui, Kwai Fung, et al.
Publicado: (2018)

Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2
por: Yang, Xi, et al.
Publicado: (2012)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?
por: Srinivas, NR
Publicado: (2015)

Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels
por: Fajardo-Robledo, Nicte S., et al.
Publicado: (2022)

Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
por: Kaur, Hardeep, et al.
Publicado: (2021)

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020)

X‐linked lymphoproliferative syndrome associated with Epstein–Barr virus encephalitis and lymphoproliferative disorder
por: Mukai, Takeo, et al.
Publicado: (2023)

Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide—Should Consideration Be Given to Cannalicular Efflux Transporters?
por: Hopkins, AM, et al.
Publicado: (2015)

EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice
por: Li, Chunrong, et al.
Publicado: (2020)

Andrographolide Inhibits Epstein–Barr Virus Lytic Reactivation in EBV-Positive Cancer Cell Lines through the Modulation of Epigenetic-Related Proteins
por: Malat, Praphatson, et al.
Publicado: (2022)

ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells
por: Van Sciver, Nicholas, et al.
Publicado: (2021)

Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012)

Epstein-Barr Virus (EBV)-associated Gastric Carcinoma
por: Iizasa, Hisashi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4ltck07dqbg5jrspor4bfr4m0k